Cargando…

Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.

Detalles Bibliográficos
Autores principales: Koeckerling, David, Pan, Daniel, Barker, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862016/
https://www.ncbi.nlm.nih.gov/pubmed/33549765
http://dx.doi.org/10.1016/j.cmi.2021.01.025
_version_ 1783647196413952000
author Koeckerling, David
Pan, Daniel
Barker, Joseph
author_facet Koeckerling, David
Pan, Daniel
Barker, Joseph
author_sort Koeckerling, David
collection PubMed
description
format Online
Article
Text
id pubmed-7862016
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78620162021-02-05 Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. Koeckerling, David Pan, Daniel Barker, Joseph Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-08 2021-02-05 /pmc/articles/PMC7862016/ /pubmed/33549765 http://dx.doi.org/10.1016/j.cmi.2021.01.025 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Koeckerling, David
Pan, Daniel
Barker, Joseph
Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title_full Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title_fullStr Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title_full_unstemmed Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title_short Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
title_sort re: ‘efficacy and safety of tocilizumab in covid-19 patients: a living systematic review and meta-analysis’ by tleyjeh et al.
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862016/
https://www.ncbi.nlm.nih.gov/pubmed/33549765
http://dx.doi.org/10.1016/j.cmi.2021.01.025
work_keys_str_mv AT koeckerlingdavid reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal
AT pandaniel reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal
AT barkerjoseph reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal